Index of artpub/2024/306334/

Motzer, Robert J
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma : Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024
https://ddd.uab.cat/record/306334